Study: NCT00868790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3577
Description: MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3577
Description: MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3577
Description: MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3577
Description: MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3577
Description: MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3577
Description: MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3577
Description: MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-3577
Description: Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-3577
Description: Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-3577
Description: Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-3577
Description: Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-3577
Description: Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-3577
Description: Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-3577
Description: Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-3577
Description: Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period